Compare, Analyse Wockhardt with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs ACTAVIS (US) - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 WOCKHARDT   ACTAVIS
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
ACTAVIS
Dec-18
WOCKHARDT/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,01214,245-   
Low Rs5329,556-   
Sales per share (Unadj.) Rs355.93,494.4-  
Earnings per share (Unadj.) Rs-60.3-1,125.5-  
Cash flow per share (Unadj.) Rs-46.8368.2-  
Dividends per share (Unadj.) Rs0.010-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs257.814,412.8-  
Shares outstanding (eoy) m110.63332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.23.4 63.7%   
Avg P/E ratio x-12.8-10.6 121.1%  
P/CF ratio (eoy) x-16.532.3 -51.1%  
Price / Book Value ratio x3.00.8 362.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m85,3793,958,164 2.2%   
No. of employees `0006.316.9 37.0%   
Total wages/salary Rs m9,3710-   
Avg. sales/employee Rs Th6,295.068,771.5 9.2%   
Avg. wages/employee Rs Th1,498.30-   
Avg. net profit/employee Rs Th-1,066.3-22,151.3 4.8%   
INCOME DATA
Net Sales Rs m39,3691,162,239 3.4%  
Other income Rs m1,20222,226 5.4%   
Total revenues Rs m40,5711,184,465 3.4%   
Gross profit Rs m1830,457 0.1%  
Depreciation Rs m1,495496,832 0.3%   
Interest Rs m2,55567,068 3.8%   
Profit before tax Rs m-2,830-511,217 0.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,582130,381 -2.7%   
Tax Rs m257-6,479 -4.0%   
Profit after tax Rs m-6,669-374,358 1.8%  
Gross profit margin %02.6 1.8%  
Effective tax rate %-9.11.3 -716.7%   
Net profit margin %-16.9-32.2 52.6%  
BALANCE SHEET DATA
Current assets Rs m33,796476,690 7.1%   
Current liabilities Rs m26,917421,695 6.4%   
Net working cap to sales %17.54.7 369.3%  
Current ratio x1.31.1 111.1%  
Inventory Days Days7920 405.1%  
Debtors Days Days8966 134.6%  
Net fixed assets Rs m39,664131,559 30.1%   
Share capital Rs m5530-   
"Free" reserves Rs m27,9680-   
Net worth Rs m28,5224,793,693 0.6%   
Long term debt Rs m21,7311,688,033 1.3%   
Total assets Rs m81,6207,493,633 1.1%  
Interest coverage x-0.1-6.6 1.6%   
Debt to equity ratio x0.80.4 216.4%  
Sales to assets ratio x0.50.2 311.0%   
Return on assets %-5.0-4.1 122.9%  
Return on equity %-23.4-7.8 299.4%  
Return on capital %-7.7-4.8 158.5%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m8,0190-   
CASH FLOW
From Operations Rs m684415,224 0.2%  
From Investments Rs m6,302228,112 2.8%  
From Financial Activity Rs m-7,695-712,649 1.1%  
Net Cashflow Rs m-664-68,967 1.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 73.62 Rs / USD

Compare WOCKHARDT With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare WOCKHARDT With: BIOCON   WYETH  SHASUN PHARMA  ALKEM LABORATORIES  ELDER PHARMA  



Today's Market

Sensex Ends 127 Points Higher; Auto Stocks Witness Huge Buying(Closing)

Share markets in India continued to trade on a positive note during closing hours today and ended their session marginally higher.

Related Views On News

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

More Views on News

Most Popular

My View on ITC (Fast Profits Daily)

Oct 23, 2020

What do the charts say about ITC?

The 'Seedhi Baat, No Bakwaas' View on ITC (Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

One of the Best Investment Opportunities in the Market Right Now (Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

Why India's Drone Revolution is a 4x Profit Opportunity (Profit Hunter)

Oct 16, 2020

My research on India's leading defence companies brought me to one major player in drone manufacturing.

More
-->

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Report: Multibagger Stock Ideas 2021
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

WOCKHARDT SHARE PRICE


Oct 23, 2020 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT

WOCKHARDT - STERLING BIOTECH COMPARISON

COMPARE WOCKHARDT WITH

FEATURED VIDEOS

Value Vs Growth Investing: And the Winner Is...

Why ITC and not HUL is my Idea of a Good Investment Right Now

Contrarian Trading in PSU Banks

Why I Asked My Subscribers to Sell Stocks and Move into Cash?

More Featured Videos

MARKET STATS